Peter Salzmann
Chief Executive Officer at Immunovant Inc.
Sits on 2 boards. Last updated September 27, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Immunovant Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Immunovant Inc. August 12, 202475.8%
-
Corbus Pharmaceuticals Holdings Inc. May 16, 202499.7%
-
Immunovant Inc. August 21, 202384.8%
-
Corbus Pharmaceuticals Holdings Inc. May 18, 202388.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 16, 2025 | Immunovant Inc. | Open-market sale | −8,321 | $14.89 | $123,900 |
| Apr 9, 2025 | Immunovant Inc. | Open-market sale | −28,094 | $12.99 | $364,941 |
| Apr 1, 2025 | Immunovant Inc. | Grant or award | +265,820 | — | — |
| Feb 19, 2025 | Immunovant Inc. | Open-market sale | −15,439 | $20.86 | $322,058 |
| Jan 15, 2025 | Immunovant Inc. | Open-market sale | −8,352 | $23.81 | $198,861 |
| Jan 15, 2025 | Immunovant Inc. | Open-market sale | −415 | $24.19 | $10,039 |
| Jan 8, 2025 | Immunovant Inc. | Open-market sale | −5,105 | $24.10 | $123,031 |
| Nov 20, 2024 | Immunovant Inc. | Open-market sale | −16,692 | $25.45 | $424,811 |
| Oct 16, 2024 | Immunovant Inc. | Open-market sale | −9,095 | $28.79 | $261,845 |
| Oct 9, 2024 | Immunovant Inc. | Open-market sale | −4,460 | $29.56 | $131,838 |
| Aug 21, 2024 | Immunovant Inc. | Open-market sale | −14,470 | $31.84 | $460,725 |
| Aug 21, 2024 | Immunovant Inc. | Open-market sale | −598 | $32.32 | $19,327 |
| Jul 17, 2024 | Immunovant Inc. | Open-market sale | −8,175 | $29.64 | $242,307 |
| Jul 17, 2024 | Immunovant Inc. | Open-market sale | −510 | $30.55 | $15,581 |
| Jul 9, 2024 | Immunovant Inc. | Open-market sale | −4,619 | $28.06 | $129,609 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.